Showing results (161-170 of 190) with videos related to
Sort By:
Pageof 19
European Journal of Cancer (Oxford, England : 1990)|June 17, 2019
The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trialsMarijke Coomans, Linda Dirven, Neil K Aaronson, et al.Journal of the National Cancer Institute|April 5, 2017
International Psychometric Validation of an EORTC Quality of Life Module Measuring Cancer Related Fatigue (EORTC QLQ-FA12)Joachim Weis, Krzysztof A Tomaszewski, Eva Hammerlid, et al.Neuro-Oncology|April 11, 2022
Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival periodMarijke B Coomans, Linda Dirven, Neil Aaronson, et al.Neuro-Oncology|November 5, 2019
Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status?Marijke B Coomans, Linda Dirven, Neil K Aaronson, et al.European Journal of Cancer (Oxford, England : 1990)|May 31, 2023
Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer typesJammbe Z Musoro, Corneel Coens, Mirjam A G Sprangers, et al.Targeted Oncology|November 9, 2020
Developing Symptom Lists for People with Cancer Treated with Targeted TherapiesSamantha C Sodergren, Sally J Wheelwright, Deborah Fitzsimmons, et al.European Journal of Cancer (Oxford, England : 1990)|November 26, 2015
The effects of age on health-related quality of life in cancer populations: A pooled analysis of randomized controlled trials using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 involving 6024 cancer patientsChantal Quinten, Corneel Coens, Irina Ghislain, et al.The Lancet. Oncology|February 7, 2017
Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trialCorneel Coens, Stefan Suciu, Vanna Chiarion-Sileni, et al.European Journal of Cancer (Oxford, England : 1990)|May 15, 2022
Clustering of EORTC QLQ-C30 health-related quality of life scales across several cancer types: Validation studyAbigirl Machingura, Mekdes Taye, Jammbe Musoro, et al.Neuro-Oncology Practice|December 11, 2020
Measuring change in health-related quality of life: the impact of different analytical methods on the interpretation of treatment effects in glioma patientsMarijke B Coomans, Martin J B Taphoorn, Neil K Aaronson, et al.Pageof 19